NCT05369858View on ClinicalTrials.gov

A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

September 4, 2021

Study Completion Date

September 11, 2021

Conditions
Healthy Male Subjects
Interventions
DRUG

[14C] SKLB1028

A single 150 mg oral dose of \[14C\] SKLB1028 containing approximately 120 microcurie of \[14C\] SKLB1028

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT05369858 - A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects | Biotech Hunter | Biotech Hunter